Efficacy and safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy-Reference-Cited by-同舟云学术

Efficacy and safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy

Published:2024-03 Issue: Volume:199 Page:113561
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Taylor Amelia M.,McKeown Janet,Dimitriou Florentia,Jacques Sarah K.,Zimmer Lisa,Allayous Clara,Yeoh Hui-Ling,Haydon Andrew,Ressler Julia M.,Galea Claire,Woodford Rachel,Kahler Katharina,Hauschild Axel,Festino Lucia,Hoeller Christoph,Schwarze Julia K.,Neyns Bart,Wicky Alexandre,Michielin Olivier,Placzke Joanna,Rutkowski Piotr,Johnson Douglas B.,Lebbe Celeste,Dummer Reinhard,Ascierto Paolo A.,Lo Serigne,Long Georgina V.,Carlino Matteo S.,Menzies Alexander M.

Publisher

Elsevier BV

Reference23 articles.

1. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III Melanoma;Dummer;N Engl J Med,2020

2. Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial;Ascierto;Lancet Oncol,2020

3. Five-year analysis of adjuvant pembrolizumab or placebo in stage III Melanoma;Eggermont;NEJM Evid,2022

4. Five-year outcomes with dabrafenib plus trametinib in metastatic Melanoma;Robert;N Engl J Med,2019

5. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study;Robert;Lancet Oncol,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial;European Journal of Cancer;2024-09

2. Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma;Annals of Oncology;2024-08